Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 2768Carcinoma, Non-Small-Cell Lung 2267Prostatic Neoplasms 1427Colorectal Neoplasms 1295Neoplasms 1260Multiple Myeloma 1086Lung Neoplasms 1050Neoplasm Metastasis 995Leukemia, Myeloid, Acute 985Lymphoma 900Melanoma 864Pancreatic Neoplasms 819Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 754Recurrence 753Leukemia 733Lymphoma, Non-Hodgkin 685Leukemia, Lymphocytic, Chronic, B-Cell 665Squamous Cell Carcinoma of Head and Neck 618Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 599Brain Neoplasms 593Carcinoma, Renal Cell 587Glioblastoma 573Rectal Neoplasms 565Sarcoma 523Myelodysplastic Syndromes 522Lymphoma, Follicular 516

Interventions

aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Multiple Primary Lung Cancers × Clear all
NCT04982900 2021-10-05

TERMGGO

Ruijin Hospital

Phase 2 Unknown
138 enrolled
Thoracic

Multiple Primary Lung Cancers

NCT04026841 2019-08-02

The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Unknown
36 enrolled
Thoracic

Multiple Primary Lung Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡